Bectas Therapeutics
Houston, US · Founded 2022 · Delaware corporation
Bectas Therapeutics is a preclinical-stage biotech company developing monoclonal antibody therapies targeting secondary immune checkpoints for cancer, paired with biomarkers to identify the patients most likely to benefit. It focuses on precision immuno-oncology across multiple solid tumor indications.
BiotechDeep TechHealthtech
Founders & leadership
JA
Jon A. BrilliantExecutive Officer
RO
Ronan O'HaganExecutive Officer, Director
RC
Ronan C. O'HaganPresident & CEO
LC
Lynda ChinDirector
Reported raises · per SEC filings
Form D private placements▶$5.5MraisedOct 2025 · 13 investors · BiotechnologyRule 506(b)
▶$5.5MraisedOct 2025 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jon A. BrilliantExecutive Officer
- Ronan O'HaganExecutive Officer, Director
- Lynda ChinDirector
- Offering amount
- $10M
- Amount sold
- $5.5M
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.